Restasis and Xiidra remain the two most widely prescribed drops for dry eye disease, but they work through different mechanisms, kick in at different speeds, and come with very different price tags. Restasis, the older option approved in 2003, uses cyclosporine to suppress inflammation and typically takes three to six months to reach full effect. Xiidra, approved in 2016, blocks a different inflammatory pathway and can produce results in as little as two to twelve weeks. For someone managing both dry eye and a neurodegenerative condition like dementia, where consistent medication routines and cost management already present daily challenges, understanding these differences is not just academic — it is genuinely practical. Dry eye disease affects an estimated 16.4 million diagnosed Americans, with undiagnosed cases potentially pushing that number as high as 49 million.
The condition disproportionately affects older adults, with prevalence rising to 18.6 percent among those 75 and older — the same population most vulnerable to Alzheimer’s disease and other forms of dementia. Women are hit harder, accounting for roughly 11.1 million of those diagnosed. For caregivers already juggling complex medication schedules, adding a twice-daily eye drop with a months-long onset window demands careful planning. This article breaks down how Restasis and Xiidra compare on cost, effectiveness, and side effects, and covers newer alternatives like Vevye and Miebo that entered the market in 2023. We will also address the particular challenges dry eye treatment poses for dementia patients and their care teams.
Table of Contents
- How Do Restasis and Xiidra Actually Work Differently for Dry Eye Disease?
- What Does Each Drop Actually Cost, and When Does Price Become a Barrier?
- Side Effects That Matter Most for Older Adults and Dementia Patients
- How to Choose Between Restasis and Xiidra When Both Are on the Table
- Newer Alternatives Worth Knowing About — Vevye, Miebo, and Cequa
- The Overlooked Challenge of Eye Drop Administration in Dementia Care
- Where Dry Eye Treatment Is Heading
- Conclusion
- Frequently Asked Questions
How Do Restasis and Xiidra Actually Work Differently for Dry Eye Disease?
Restasis contains cyclosporine at a 0.05 percent concentration. It is an immunosuppressant that blocks immune cells from releasing interleukin-2, a signaling molecule that drives the kind of chronic ocular surface inflammation responsible for suppressing tear production. Think of it as turning down the volume on an overactive immune response in the eye. The trade-off for that indirect approach is time — most patients need three to six months of consistent, twice-daily use before they notice meaningful improvement. That is a long runway, and many people abandon the medication before it has a chance to work. Xiidra takes a more targeted route. Its active ingredient, lifitegrast, is a lymphocyte function-associated antigen-1 antagonist.
In plainer terms, it physically blocks the protein LFA-1 from latching onto another protein called ICAM-1 on the surface of eye tissue. That interaction is a key step in the inflammatory cascade that damages tear-producing cells. By interrupting it directly, Xiidra tends to work faster — patients in clinical trials reported symptom relief in as little as two weeks, with most seeing results within twelve weeks. No direct head-to-head clinical trial has ever compared the two drugs against each other. That gap means every comparison relies on indirect evidence from separate studies, which limits how confidently anyone can declare a winner. What the data does show is that both are considered safe for long-term use and both require twice-daily dosing — one drop in each eye. The real differences come down to onset speed, cost, side effects, and whether a generic option matters to you.
What Does Each Drop Actually Cost, and When Does Price Become a Barrier?
Cost is where these two medications diverge sharply. Brand-name Restasis runs roughly $411 to $768 per month without insurance, depending on the pharmacy and packaging. However, the FDA approved generic cyclosporine ophthalmic emulsion in February 2022, which brought that range down to approximately $87 to $245 per month with available coupons. For patients on fixed incomes or those managing the financial burden of dementia care alongside their own health needs, that generic option can be the difference between affording treatment and going without. Xiidra has no generic equivalent. None.
Its monthly cost without insurance lands between $705 and $1,017. Both manufacturers offer copay savings cards that can reduce out-of-pocket costs to as little as zero dollars per month for commercially insured patients, but those programs do not help everyone. Medicare beneficiaries, for instance, typically cannot use manufacturer copay cards, and Medicaid coverage varies by state. If your insurance requires prior authorization — and many plans do for both drugs — you may face weeks of paperwork before coverage is confirmed. Here is the warning worth underscoring: if you are a caregiver managing finances for someone with dementia who also has dry eye disease, do not assume insurance will simply cover whichever drop the ophthalmologist prescribes. Many plans prefer one medication over the other and may require a step therapy process, meaning the patient must try and fail on the cheaper option before the plan will approve the more expensive one. Ask the prescriber’s office to run a benefits check before the prescription is sent to the pharmacy.
Side Effects That Matter Most for Older Adults and Dementia Patients
Restasis is generally well tolerated. Its most common side effects are burning and stinging upon instillation and temporary eye redness. Those sensations are brief and tend to lessen over time, but they can be distressing for a person with dementia who may not understand why their eyes suddenly sting twice a day. A caregiver applying drops for someone who cannot self-administer should expect some resistance, particularly in the early weeks. Xiidra carries a side effect that rarely gets enough attention in general discussions: dysgeusia, or altered taste. Up to 25 percent of patients experience it.
The taste disturbance is often described as a bitter or metallic flavor that appears shortly after the drops are instilled, because the medication can drain through the nasolacrimal duct into the throat. For someone with dementia who already struggles with appetite, nutrition, and the willingness to eat, an unexplained bad taste in the mouth could further reduce food intake. Other reported side effects include blurred vision, eye irritation, headaches, and sinusitis. For a cognitively intact patient, these side effects are manageable annoyances. For someone with moderate to advanced dementia, they introduce complications that may not be worth the trade-off. A person who cannot articulate that their food tastes wrong, or who becomes agitated during eye drop administration without understanding why, may end up worse off. This is a conversation worth having honestly with the prescribing physician.
How to Choose Between Restasis and Xiidra When Both Are on the Table
The decision usually comes down to four factors: how quickly you need relief, how much you can afford to pay, which side effects you can tolerate, and what your insurance will cover. If cost is the primary concern and you can wait several months for improvement, generic cyclosporine — the Restasis equivalent — is the most financially accessible prescription option. At $87 to $245 per month, it costs a fraction of what Xiidra runs, and the clinical evidence supports its long-term effectiveness. If speed matters more — say, a patient is experiencing significant discomfort that affects sleep, reading, or quality of life — Xiidra’s faster onset of two to twelve weeks is a genuine advantage. But that advantage comes at a steep price, both financially and in terms of the dysgeusia risk.
For dementia caregivers weighing these options on behalf of a loved one, the calculus often tips toward Restasis or its generic simply because the slower onset is less problematic than the taste disturbance or the cost burden. Insurance formulary placement can override all of this. Some plans cover Xiidra at a lower tier than Restasis, or vice versa. Prior authorization requirements are common for both. The practical move is to ask the ophthalmologist’s office which drug the patient’s plan prefers, request the prior authorization upfront, and have a backup plan in case the first choice is denied.
Newer Alternatives Worth Knowing About — Vevye, Miebo, and Cequa
The dry eye treatment landscape shifted meaningfully in 2023 with two new FDA approvals. Vevye, developed by Novaliq, is a preservative-free, water-free cyclosporine solution at a higher 0.1 percent concentration than Restasis. Its standout claim is speed: clinical data showed efficacy as early as four weeks, with up to 71.6 percent of patients demonstrating clinically meaningful improvement in that timeframe. That collapses the three-to-six-month waiting period associated with Restasis into something far more manageable. Miebo, manufactured by Bausch + Lomb, represents an entirely different approach. It is the first FDA-approved drop specifically targeting tear evaporation caused by Meibomian gland dysfunction — a condition where the oil-producing glands in the eyelids do not function properly, causing tears to evaporate too quickly.
Phase 3 trials (named GOBI and MOJAVE) showed significant improvement versus control as early as day 15. For patients whose dry eye is primarily evaporative rather than inflammatory, Miebo addresses a root cause that neither Restasis nor Xiidra was designed to treat. Cequa, approved in June 2019, sometimes gets overlooked in these discussions. It uses cyclosporine at 0.09 percent — slightly higher than Restasis — delivered through nanomicellar technology designed to improve corneal penetration. However, these newer options share a limitation: they are all brand-name only, with no generics available, and their long-term cost profiles and insurance coverage are still evolving. Ask your ophthalmologist whether any of these alternatives make sense before assuming Restasis or Xiidra are the only choices.
The Overlooked Challenge of Eye Drop Administration in Dementia Care
Administering eye drops to someone with moderate or advanced dementia is harder than most treatment guides acknowledge. The patient may not understand the instruction to tilt their head back, may reflexively close their eyes or turn away, and may become agitated by the sensation of liquid entering the eye. Twice-daily dosing — the requirement for both Restasis and Xiidra — means this scenario plays out at least fourteen times per week.
Some caregivers find that warming the drops to room temperature before instillation reduces the initial sting, particularly with Restasis. Others have had success applying the drop to the inner corner of a closed eye and then gently asking the person to blink, allowing the medication to flow in naturally. Occupational therapists who specialize in dementia care can sometimes suggest patient-specific techniques. If administration becomes a persistent source of distress, it is worth discussing with the ophthalmologist whether the benefits of the medication justify the daily struggle, or whether a different treatment modality — such as punctal plugs or warm compress therapy — might achieve adequate relief with less friction.
Where Dry Eye Treatment Is Heading
The pipeline beyond 2023 approvals suggests that dry eye treatment will continue to diversify. Researchers are investigating drops that target different inflammatory pathways, longer-acting formulations that could reduce dosing frequency, and combination therapies that address both the inflammatory and evaporative components of the disease simultaneously.
For the aging population most affected by both dry eye and cognitive decline, any reduction in dosing burden would be a meaningful quality-of-life improvement. The broader trend is toward personalization — identifying whether a patient’s dry eye is primarily inflammatory, evaporative, or mixed, and matching the treatment accordingly. That shift matters for dementia patients and their caregivers, because it may eventually mean fewer medications, fewer daily administrations, and less trial-and-error with drugs that take months to show whether they are working.
Conclusion
Restasis and Xiidra both treat dry eye disease effectively, but through different mechanisms and on different timelines. Restasis and its generic equivalent offer a more affordable, well-established option that requires patience — three to six months — to see full results. Xiidra works faster but costs significantly more, has no generic, and carries a notable risk of taste disturbance that can be particularly problematic for older adults with dementia. Newer options like Vevye and Miebo are expanding the field, but remain brand-name only and are still building their insurance coverage track records.
For caregivers navigating dry eye treatment alongside dementia care, the decision should account for more than just clinical efficacy. Cost sustainability, ease of administration, side effect tolerability, and insurance coverage all deserve equal weight in the conversation with the prescribing physician. No single drop is universally best. The right choice depends on the individual patient’s type of dry eye, their overall health picture, their care situation, and what their insurance will realistically cover.
Frequently Asked Questions
Can I use Restasis and Xiidra together?
There is no standard clinical protocol for combining them, and using both simultaneously has not been studied in controlled trials. Some ophthalmologists have prescribed them together off-label, but this should only be done under direct medical supervision. Do not combine prescription eye drops without consulting your doctor.
Will over-the-counter artificial tears work instead of Restasis or Xiidra?
Artificial tears provide temporary symptom relief by supplementing moisture, but they do not address the underlying inflammation driving chronic dry eye disease. For mild cases, they may be sufficient. For moderate to severe dry eye, prescription drops that target inflammation are generally necessary for long-term management. Many patients use both — artificial tears for immediate comfort and a prescription drop for disease modification.
How long do I need to use Restasis or Xiidra?
Both are designed for long-term, ongoing use. Dry eye disease is typically a chronic condition, and stopping the medication usually means symptoms will return. Neither drug is a cure — they manage the disease for as long as you continue using them.
Are these drops safe for someone with dementia who takes multiple other medications?
Both Restasis and Xiidra have minimal systemic absorption, meaning very little of the medication enters the bloodstream. Drug interactions with oral medications are not a significant concern. However, the practical challenges of administering eye drops to a person with cognitive impairment — and the potential for Xiidra’s taste disturbance to affect appetite — are legitimate considerations to discuss with the care team.
Does Medicare cover Restasis or Xiidra?
Medicare Part D plans may cover one or both, but coverage varies widely by plan. Prior authorization is commonly required. Generic cyclosporine is more likely to be covered at a lower tier than brand-name Restasis or Xiidra. Check the specific plan’s formulary or ask the prescriber’s office to verify coverage before filling the prescription.
